Dr Trevor Phillips, Executive Chairman
Dr Trevor Phillips became a Non-Executive Director of hVIVO plc in June 2017 and Executive Chairman in November 2017. Trevor has over thirty years of experience within the pharmaceutical industry, including extensive international drug development and corporate development responsibilities. He was previously Chief Operations Officer and President of US Operations, as well as a member of the Board, at Vectura Group plc, a FTSE 250 company listed on the London Stock Exchange focused on respiratory diseases. Subsequent to joining Vectura in 2010, Trevor played an integral leadership role in the company’s successful development, including the acquisition of Activaero GmbH in 2014 and the merger with Skyepharma plc in 2016.
Prior to joining Vectura, Trevor held the roles of Chief Executive Officer and Chief Operating Officer at Critical Therapeutics, Inc. (now Chiesi USA, Inc.), a US listed specialty pharmaceutical company, where he was involved in setting up commercial partnerships, product in-licensing and out-licensing, managing drug development, commercial product manufacturing and M&A activity. He led the merger of Critical Therapeutics with Cornerstone BioPharma Holdings. He has also held senior management positions at Sepracor, Inc. (now Sunovion Pharmaceuticals, Inc.), Accenture plc and GlaxoWellcome plc (now GlaxoSmithKline plc).
Trevor trained as a microbiologist at University of Reading, obtaining a PhD in microbial biochemistry from the University of Wales in 1986. He was awarded an MBA from Henley Management College in 1997.
John Efthimiou, Executive Vice President, Translational Medicine
John joined hVIVO as Executive Vice President, Translational Medicine in October 2015. He is a physician and accredited respiratory specialist with over 15 years of broad clinical experience in the care of patients with respiratory and infectious diseases, cardiology, rheumatology and general medicine in London and Oxford teaching hospitals.
Subsequent to his successful clinical career, he has had over 25 years broad Research and Development and Clinical Development leadership experience with major pharmaceutical companies (GSK, Novartis, Roche/Chugai, Alimirall), as well with small pharma and biotech companies to CMO/Board level positions. He has been involved in the successful development, regulatory approval and commercialisation of over 100 new medicines particularly in the areas of respiratory, allergy, infectious diseases, rheumatology, inflammation, metabolic/endocrine and cardiovascular diseases.
John gained a BSc (1st Class Hons) in Biochemistry and MB, BS medical degrees from Guy’s/University of London and was later awarded a MD from the University of London and appointed FRCP by the Royal College Physicians, London. His major research and development interests have been in asthma, COPD, cystic fibrosis, allergic, bacterial and viral infectious disorders and in developing novel biomarkers and therapies to manage these. In recent years he has also developed an interest in medical communications, patient and doctor lexicons, and in enhancing patient-doctor dialogue and adherence.
Chris Poll, Executive Vice President, Research & Development
Chris joined hVIVO (formerly Retroscreen Virology) as Vice President, Research and Development Operations in August 2013 and was promoted to Executive Vice President, Research and Development in January 2015.
He has over 28 years research and research leadership experience in drug discovery with major pharmaceutical companies (Glaxo, Sandoz, Bayer, Novartis) in the areas of respiratory disease, inflammation and immunology research.
Prior to joining hVIVO Chris was Executive Director and Head of COPD Research at Novartis Institutes for Biomedical Research where he was responsible for a portfolio of COPD projects from exploratory activities up to the selection of candidates for proof of concept clinical studies. Before joining Novartis he was Head of the Respiratory Pharmacology Department at Bayer.
Chris gained a BSc (Hons) degree in Physiology and Biochemistry from the University of Southampton in 1980 and received his PhD from the University of London in 1986 studying the role of calcium in stimulus-response coupling in human platelets. He is also an honorary senior lecturer in the airway disease section of the National Heart and Lung Institute, Imperial College, London.
Reid Tripp, Executive Vice President, Business Development & Marketing
Reid has more than 25 years of international experience within the life science industry and has an MBA.
Before joining hVIVO, he held senior management business development and marketing positions with various large , mid-sized and small global Clinical Research Organisations where he successfully built and managed sales , marketing, proposals and contracts teams, delivered hundreds of millions in contractual relationships and overall, enhanced customer satisfaction. Reid has also served in a senior management role at a start-up biotechnology company and has held various management positions for a large pharmaceutical company.
Graham Yeatman, Chief Financial & Business Officer (and PLC Board Director)
Graham joined hVIVO Services Limited (formerly Retroscreen Virology Limited) as Finance Director in May 2011 and became Finance Director of hVIVO plc (formerly Retroscreen Virology Group plc) in April 2012. Graham was promoted to Chief Financial and Business Officer in January 2015.
Graham has significant experience of building businesses for rapid growth and profitability. He is a Chartered Accountant and trained and worked with PricewaterhouseCoopers for thirteen years across its audit, tax, consultancy, business process reengineering and outsourcing divisions. In 2001 he joined buyingTeam Limited (subsequently renamed Proxima) as Finance & Operations Director and was influential in growing the business to become one of the UK’s leading purchasing services providers. In 2006 he joined Neuropharm Group plc as Chief Financial Officer. Graham has a First in Economics and Maths from Bristol University.